Praxis Bioresearch Obtains FDA Clearance On the IND Application for Its Lead Candidate PRX-P4-003 In Alzheimer’s Disease Apathy Sandeep PatilOctober 29, 2024
Praxis Bioresearch Expands its Board of Directors with Appointment of Adam Levy Sandeep PatilSeptember 20, 2023
Praxis Bioresearch Presents Phase 0 Clinical Data for PRX-P4-003 at 14th Annual CTAD conference Sandeep PatilNovember 9, 2021
Praxis Bioresearch Awarded $2.9 Million Fast-Track SBIR Grant for Development of Novel Therapy for Apathy in Alzheimer’s Disease Sandeep PatilAugust 5, 2021
Praxis Bioresearch Announces Positive Results From Clinical Microdose Study In Humans Showing Oral Activation Of Its Novel Prodrug Stimulant PRX-P4-003 Sandeep PatilJune 23, 2021
Praxis Bioresearch Announces Issuance of U.S. Patent on its Prodrug Stimulant PRX-P4-003 Cassandra CortrightJune 23, 2020
Praxis Bioresearch Awarded $1.5 Million Fast-Track SBIR Grant for Development of Novel Prodrug Stimulant with Abuse-Deterrent Properties Sandeep PatilAugust 7, 2018
Praxis Bioresearch Announces Peer-Reviewed Publication of Positive Data for Novel Prodrug Stimulant with Abuse-Deterrent Properties Sandeep PatilMarch 28, 2018
Praxis Bioresearch Presents Positive Preclinical Data for Novel Prodrug Stimulant with Abuse-Deterrent Properties at ACNP Annual Meeting Sandeep PatilDecember 7, 2017
